Roche, Chiasma partner to develop, commercialise Octreolin

Roche and Chiasma have partnered to develop and commercialise Octreolin, an investigational oral regimen for acromegaly and neuroendocrine tumours.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news

Related Links:

Authors: Lamas C, García-Martínez A, Cámara R, Fajardo-Montanana C, Viguera L, Aranda I Abstract Silent somatotroph pituitary neuroendocrine tumors (or silent growth hormone pituitary neuroendocrine tumors, SGH-PitNET) are neoplasias with positive immunostaining for growth hormone (GH), in patients with no signs and symptoms of acromegaly nor biochemical evidence of GH hypersecretion. From a clinical stand-point they are considered and managed as non-functioning pituitary tumors, since they usually come to evidence due to mass-effects (headache, visual impairment, hypopituitarism) or as asympto...
Source: Minerva Endocrinologica - Category: Endocrinology Tags: Minerva Endocrinol Source Type: research
Authors: Puig-Domingo M, Marazuela M Abstract Acromegaly is a chronic disorder usually diagnosed late in the disease evolution, leading to substantial morbidity and mortality related to this long period of undiagnosed state as well as the difficulty in achieving normalization of GH hypersecretion and controlling tumour mass. First generation somatostatin analogues (SSA) are accepted as the first-line medical therapy or as second-line therapy in patients undergoing unsuccessful surgery. However, because a high percentage of patients experience SSA treatment failure, the inclusion of biomarkers associated with a succ...
Source: Minerva Endocrinologica - Category: Endocrinology Tags: Minerva Endocrinol Source Type: research
In conclusion, the SSTR expression profile and morphological subtypes of the somatotroph tumor may help predict the response to medical treatment. Such pathological profiling could become a useful decision-making tool for clinicians in the context of a multidisciplinary approach, after surgery failure. PMID: 30531694 [PubMed - as supplied by publisher]
Source: Minerva Endocrinologica - Category: Endocrinology Tags: Minerva Endocrinol Source Type: research
Acromegaly is a rare endocrine disorder that is often misunderstood. Medscape interviewed Dr Laurence Katznelson to get the facts you need to know.Medscape Diabetes &Endocrinology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology Expert Interview Source Type: news
Publication date: Available online 10 December 2018Source: Molecular and Cellular EndocrinologyAuthor(s): Christoph Schmid, Claudia Ghirlanda, Cornelia Zwimpfer, Oliver Tschopp, Richard A. Zuellig, Markus NiessenAbstractCystatin C (CysC) is a marker for estimation of glomerular filtration rate (GFR). CysC levels may depend not only on clearance/GFR but possibly also on changes in production. Our studies on tissue distribution of CysC protein in mice showed that adipose tissue expresses significant amounts of CysC, suggesting that adipocytes could contribute to circulating CysC levels in vivo. As growth hormone (GH) and tri...
Source: Molecular and Cellular Endocrinology - Category: Endocrinology Source Type: research
Conclusions: Old age and radiographic predictors indicating large tongue size (large TA, long alveolar line of the mandible to the hyoid bone and mandible to the hyoid bone) were associated with an increased rate of difficult laryngoscopy in acromegaly patients. Preoperative radiographic measurements of tongue size can be helpful for safe airway management in such patients.
Source: Journal of Neurosurgical Anesthesiology - Category: Anesthesiology Tags: Clinical Investigations Source Type: research
ConclusionOctreotide SC depot provided higher exposure (AUC) than octreotide IM, maintained biochemical control in patients with acromegaly and symptom control in patients with functioning NETs, and was well tolerated with a safety profile consistent with octreotide IM.ClinicalTrials.gov identifierNCT02299089.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
ConclusionsIn patients with newly diagnosed acromegaly, HT frequency was significantly increased and it was independently associated with the RRI value. Therefore, these patients should be closely monitored for HT —the most frequent and important cardiovascular risk factor—and treated before they develop target organ damage.
Source: High Blood Pressure and Cardiovascular Prevention - Category: Cardiology Source Type: research
Authors: Boguszewski CL, Boguszewski MCDS Abstract Several components of the GH axis are involved in tumor progression and GH-induced intracellular signaling has been strongly associated with breast cancer susceptibility in genome-wide association studies. In the general population, high IGF-I levels and low IGFBP-3 levels within the normal range are associated with the development of common malignancies, and components of the GH-IGF signaling system exhibit correlations with clinical, histopathological and therapeutic parameters in cancer patients. Despite promising findings in preclinical studies, anti-cancer the...
Source: Endocrine Reviews - Category: Endocrinology Tags: Endocr Rev Source Type: research
Authors: García-Alvarez M, Climent V Abstract Acromegaly is a rare disease characterized by high levels of growth hormone (GH) and insulin- like growth factor 1 (IGF-1). The excess of GH leads to the development of different manifestations in different organs, from subtle signs in the bones and soft tissues to the development of respiratory and cardiac insufficiency. In the cardiovascular system, the GH/IGF-1 axis exerts its influence on three major aspects: myocyte growth and structure, cardiac contractility and vascular function. In this article, we review the different cardiovascular and respiratory compl...
Source: Minerva Endocrinologica - Category: Endocrinology Tags: Minerva Endocrinol Source Type: research
More News: Acromegaly | Neurology | Pharmaceuticals